[Combined treatment of nephrolithiasis with canephron H].
A total of 35 nephrolithiasis patients aged 26-64 years entered the trial. They were divided into three groups: patients of group 1 (n = 12) received canephron H (50 drops or 2 dragees 3 times a day for 1 month), patients of group 2 (n = 11) were exposed to extracorporeal shock wave lithotripsy (ESWL) followed by standard spasmolytic therapy, patients of group 3 (n = 12) were given canephron H for 1 month before ESWL and 1 month after it in combination with standard therapy. In addition to standard examinations, measurements were made of urinary alkaline phosphatase, lactate dehydrogenase, gamma-glutamyltransferase, N-acetyl-beta-D-glucosaminidase, leucinaminopeptidase. At admission, patients of the three groups had high enzymuria. A course of canephron therapy reduced urinary enzyme levels in groups I and 3 to control levels. Within 24 hours since ESWL patients of groups 2 and 3 demonstrated growth of urinary enzymes (p < 0.05) but in group 3 this rise was less pronounced. On postoperative day 7 enzymuria in groups 2 and 3 diminished (in group 3 enzymuria was close to normal) while in group 2 it was elevated. Thus, canephron H reduces enzymuria and can be used in combined treatment of nephrolithiasis.
Neĭmark
A I
AI
Kablova
I V
IV
D000328:Adult; D004798:Enzymes / Q000652:urine; D005260:Female; D006801:Humans; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D053040:Nephrolithiasis / Q000628:therapy* / Q000652:urine; D010936:Plant Extracts / Q000008:administration & dosage*; D011507:Proteinuria / Q000628:therapy / Q000652:urine
D004798:Enzymes; D010936:Plant Extracts; C020245:canephron N